Position in ZYME
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,705,582
-$793,284 QoQ
Shares Held
65,248
-34.6% QoQ
Ownership
0.092%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#76
of 202 holders
Holding Since
Dec 2023
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ZYME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Susquehanna Portfolio Strategies, LLC holds $404,884,857 across 122 Biotechnology names. ZYME ranks #46 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
90,928 | $45,166,665 | |
| 2 | MRNA |
Moderna, Inc.
|
471,043 | $32,987,141 | |
| 3 | CORT |
Corcept Therapeutics Inc
|
211,017 | $18,347,928 | |
| 4 | BBIO |
BridgeBio Pharma, Inc.
|
226,869 | $16,897,203 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
273,562 | $15,653,217 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
166,503 | $13,032,189 | |
| 7 | EXEL |
Exelixis, Inc.
|
229,749 | $12,500,643 | |
| 8 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
22,003 | $11,814,510 |
All Filings in ZYME
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,705,582 | 65,248 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $2,498,866 | 99,795 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $2,627,602 | 99,795 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $1,438,050 | 84,195 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $1,075,886 | 85,728 | Shares | Sole | 2025-08-14 | |
| 2024-09-30 | $309,621 | 24,671 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $209,950 | 24,671 | Shares | Defined | 2024-08-15 | |
| 2024-03-31 | $286,112 | 27,197 | Shares | Defined | 2024-05-07 | |
| 2023-12-31 | $282,576 | 27,197 | Shares | Defined | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||